Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
International Journal of Rheumatic Diseases|November 29, 2021
Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registryFlavia V Castelino, John M VanBuren, Emily Startup, et al.
Clinical and Experimental Rheumatology|July 27, 2023
The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessationSarah Luebker, Tracy M Frech, Shervin Assassi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Rheumatology (Oxford, England)|April 20, 2023
CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilizationSarah Luebker, Tracy M Frech, Shervin Assassi, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 21, 2021
ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statementsMaria M Crespo, Erika D Lease, Amparo Sole, et al.
The Journal of Rheumatology|January 15, 2025
Psychometric Evaluation of the Scleroderma Skin Questionnaire: A Novel Patient-Reported Outcome for Skin Disease in Patients With Systemic SclerosisJeong Min Yu, John M VanBuren, Angela Child, et al.
The Journal of Rheumatology|November 15, 2025
Type III and type VI collagen neoepitopes are associated with disease severity in systemic sclerosisAli Y Ayla, Elana J Bernstein, Meng Zhang, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2025
Hand swelling and other non-Raynaud's symptoms as the initial presentation of systemic sclerosis: prevalence and clinical associations in two U.S. cohortsIqtidar Hanif, Shervin Assassi, Maureen D Mayes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Pageof 4